On this page
Quick Reference
Overview and Recommendations
Background
- •Palliative care should be integrated at diagnosis for advanced esophageal cancer, especially with metastatic disease, poor performance status, or significant symptom burden, as prognosis is poor: median overall survival with best supportive care is only 3 months, with palliative radiotherapy 7 months, and with first-line systemic therapy 7.5 months.
- •Malignant dysphagia is the dominant symptom; palliative stenting achieves rapid improvement in the Mellow-Pinkas dysphagia score from median 3 to 0 within 4 weeks, with successful palliation in 76.8% of patients.
- •Radiotherapy, including external beam and brachytherapy, provides durable local control and can prolong survival when added to chemotherapy in patients with controlled metastatic disease (median OS 23.3 vs 14 months).
- •Systemic therapy for metastatic disease should favor doublet chemotherapy over triplet regimens due to similar survival (HR 0.92) and significantly less grade 3-5 toxicity (21% vs 33%).
- •The decision to transition to best supportive care arises when performance status declines, disease progresses, or complications become unmanageable; early palliative care involvement facilitates advance care planning.
Evaluation
- •Suspect need for palliative care in any patient with advanced esophageal cancer, particularly those with metastatic disease, WHO performance status 2-4, or significant symptom burden such as dysphagia, pain, or weight loss.
- •Assess dysphagia severity using the Mellow-Pinkas score (0 = able to eat normal diet, 4 = complete dysphagia) to guide stenting decisions.
- •Evaluate bleeding risk before endoscopic resection: DOAC use (especially apixaban, OR 101.7), warfarin, resection wound circumference ≥3/4, and specimen size ≥40 mm are significant risk factors.
- •Order baseline labs including hemoglobin, renal function, and coagulation profile; for patients on antithrombotics, plan perioperative management.
- •Assess performance status using WHO or ECOG scale to determine suitability for active treatment versus best supportive care.
- •Obtain imaging (CT chest/abdomen, PET-CT) to define extent of metastatic disease and guide local palliative interventions.
- •Evaluate for tracheoesophageal fistula with contrast swallow or CT if suspected; covered stents are preferred for fistulas.
- •Screen for brain metastases in patients with neurological symptoms; incidence is 2.84% overall, higher in adenocarcinoma (5.34%).
- •Assess nutritional status: weight, caloric intake, swallowing function; consider enteral feeding if significant dysphagia.
- •Evaluate psychosocial distress using HRQoL profiles; identify patients at risk for stable-low (5%) or deteriorating (14%) trajectories who need intensified support.
- •Consider ctDNA levels for prognostic refinement in refractory disease: highest quartile ctDNA associated with shorter survival (median OS 5.5 vs 9.9 months).
Management
- •Initiate palliative care at diagnosis for advanced disease; integrate symptom management, nutritional support, and psychosocial services from the start.
- •For malignant dysphagia, place self-expanding metal stent (SEMS) as first-line; covered stents reduce tumor ingrowth and are preferred for fistulas.
- •Use low radial force stents (e.g., Niti-S) in patients with prior radiotherapy to reduce major adverse events (6.3% vs 5.9%).
- •Consider radioactive stents (iodine-125) to reduce restenosis (11.9% vs 27.0%; HR 0.387).
- •After stenting, offer additional palliative treatment (chemotherapy or radiotherapy) to prolong stent patency (143.3 vs 67.6 days) and overall survival (169.0 vs 96.4 days).
- •For patients with controlled metastatic disease, add palliative external beam radiotherapy to the primary tumor to improve median OS (23.3 vs 14 months) and time to local progression.
- •Use high-dose-rate brachytherapy (e.g., 3×5 Gy boost or 6×5 Gy exclusive) for reirradiation or when EBRT is not feasible; median OS 15 months overall.
- •For systemic therapy, use doublet chemotherapy (e.g., fluoropyrimidine + platinum) over triplet regimens; avoid triplets due to higher toxicity without survival benefit.
- •Manage post-ESD bleeding endoscopically with cauterization (86%) or clipping (14%); hospitalize and transfuse as needed.
- •For patients on DOACs undergoing endoscopic resection: hold DOAC day before procedure, resume on postoperative day 1 after confirming no bleeding; consider switching from apixaban to dabigatran if high risk.
- •For post-ESD stricture, perform serial endoscopic balloon dilation; consider steroid injection or oral steroids for refractory cases.
- •Manage pain with multimodal approach: opioids for nociceptive pain, gabapentinoids or corticosteroids for neuropathic pain, NSAIDs with caution.
- •Provide nutritional support: enteral feeding via nasogastric tube or percutaneous gastrostomy for patients with significant dysphagia; in terminal phase, focus on oral comfort care.
- •Address psychosocial distress: refer to psychology, social work, or peer support programs; use HRQoL trajectories to identify patients needing intensified support (stable-low 5%, deteriorating 14%).
- •For dumping syndrome after esophagectomy: dietary modifications (small frequent meals, low simple sugars), acarbose, octreotide for refractory cases.
- •For reflux after esophagectomy: proton pump inhibitors, prokinetics, head-of-bed elevation.
- •For brain metastases: consider resection (HR 0.45 for survival), whole-brain radiotherapy, corticosteroids; multiple metastases and extracranial disease worsen prognosis.
- •Refer to hospice when life expectancy is ≤6 months: median survival with best supportive care is 3.2 months; do not wait until all active treatment is exhausted.
- •Avoid: resuming DOACs on procedure day; routine PPI or hemostatic agents after ESD; underestimating late bleeding risk (up to day 17); using triplet chemotherapy over doublet.
Board Review — High Yield
- •Early palliative care, Integrate at diagnosis of advanced esophageal cancer; median survival with best supportive care is only 3 months.
- •Mellow-Pinkas score, Dysphagia grading (0-4); stenting improves from median 3 to 0 within 4 weeks.
- •DOACs and post-ESD bleeding, DOAC use (especially apixaban) is strongest risk factor; hold day before, resume POD1.
- •Covered stents, Preferred for tracheoesophageal fistula; reduce tumor ingrowth.
- •Low radial force stents, Use after radiotherapy to reduce adverse events (6.3%).
- •Doublet over triplet, Similar survival, less toxicity (21% vs 33% grade 3-5).
- •HRQoL trajectories, 65% stable-high, 5% stable-low, 10% improving, 14% deteriorating, 6% fluctuating; identify at-risk patients.
- •Brain metastases, Incidence 2.84%; resection improves survival (HR 0.45); whole-brain RT for multiple.
- •ctDNA prognosis, Highest quartile ctDNA in refractory disease: median OS 5.5 vs 9.9 months.
- •Hospice referral, Median survival 3.2 months with best supportive care; refer when life expectancy ≤6 months.
Deep Dive — Evidence Details
When to Integrate Palliative Care
- ▸Integrate palliative care at diagnosis for advanced disease.
- ▸Stenting provides rapid dysphagia relief; additional therapy prolongs patency and survival.
Palliative care should be integrated at diagnosis for advanced , especially with metastatic disease, poor performance status, or significant symptom burden. Median overall survival for best supportive care is only 3 months and for palliative radiotherapy alone is 7 months [1]B2b. For synchronous metastatic disease on first-line systemic therapy, median OS is 7.5 months [9]D5. Palliative stenting improves dysphagia: Mellow-Pinkas score from median 3 to 0 within 4 weeks, with 76.8% success [3]C4. Additional palliative treatment after stenting prolongs stent patency (67.6 to 143.3 days) and OS (96.4 to 169.0 days) [8]B3b. Radiotherapy before stenting increases severe chest pain (7.6% vs. 1.6%); after stenting increases ingrowth/overgrowth (26.1% vs. 11.5%) and reflux (8.7% vs. 1.1%) [4]C4. Low-radial-force stents after RT have only 6.3% major adverse events [10]D5. Doublet chemotherapy is preferred over triplet due to similar survival (HR 0.92) and less grade 3-5 toxicity (21% vs. 33%) [9]D5. Pearl: For patients with advanced esophageal cancer, integrate palliative care at diagnosis, especially if dysphagia is present or performance status is poor, because early stenting, radiotherapy, or systemic therapy can improve symptoms and prolong survival, but the window for effective palliation narrows as disease burden increases.
Symptom Management
- ▸DOAC use is the strongest risk factor for post-ESD bleeding.
- ▸Stricture management requires serial balloon dilation.
Bleeding: Post-ESD bleeding rate is 0.5% (median onset day 8) [15]C4. Risk factors include DOAC use (OR 41.9), warfarin (OR 26.4), apixaban (OR 101.7), resection wound circumference ≥3/4 (OR 15.3), and specimen size ≥40 mm (OR 6.5) [15]C4. DOACs are the strongest modifiable risk factor; apixaban carries highest risk. Bleeding controlled endoscopically (cauterization 86%, clipping 14%) [15]C4. Dysphagia and stricture: Stricture occurs in 6-7% after ESD, especially with defects >3/4 circumference; managed with serial balloon dilation [16]D5[18]D5. Pain: Minimally invasive esophagectomy reduces postoperative pain compared to open [19]D5. Nutritional support: Assess weight, caloric intake, swallowing; consider enteral feeding for significant dysphagia. What NOT to do: Do not resume DOACs on procedure day; wait until POD1 after confirming no bleeding [15]C4. Do not routinely use PPI or hemostatic agents [15]C4. Monitoring: Blood tests POD1; discharge day 4; extended monitoring for high-risk patients up to 2 weeks [15]C4.
Pearl: DOAC use is the strongest risk factor for post-ESD bleeding (OR 41.9); for patients on apixaban with large or near-circumferential lesions, consider switching to dabigatran if feasible, and plan for close post-discharge monitoring through day 14 [15]C4.
Psychosocial, Spiritual, and Caregiver Support
- ▸Five HRQoL recovery patterns guide psychosocial monitoring.
- ▸Caregiver burden should be assessed and addressed.
Health-related quality of life (HRQoL) after treatment follows distinct trajectories. In a nationwide cohort, two cross-sectional profiles emerged: high-HRQoL (78-84%) and low-HRQoL (16-22%) [26]B2b. Longitudinal analysis identified five recovery patterns: stable-high (65%), stable-low (5%), improving (10%), deteriorating (14%), and fluctuating (6%) [26]B2b. Poorer HRQoL associated with female sex and lower BMI; fluctuating HRQoL associated with surgery [26]B2b. These profiles help identify patients needing enhanced psychosocial support. Spiritual and existential support: Explore sources of meaning, hope, fear; offer chaplaincy referral. Caregiver burden: Assess for burnout, depression, social isolation; offer respite care, counseling, support groups. Pearl: The five HRQoL profiles identified by Deuning-Smit et al., stable-high (65%), stable-low (5%), improving (10%), deteriorating (14%), and fluctuating (6%), provide a framework for anticipating which patients may need intensified psychosocial support after esophageal cancer treatment [26]B2b.
Palliative Procedures
- ▸SEMS are first-line for dysphagia; covered stents preferred for fistulas.
- ▸Palliative RT improves survival in metastatic disease responding to chemotherapy.
Self-expanding metal stents (SEMS): Mainstay for malignant dysphagia and tracheoesophageal fistulas. Technical success >98%, clinical success >90% [3]C4[8]B3b[12]D5. Covered stents reduce tumor ingrowth; low radial force stents recommended after radiotherapy (major adverse events 6.3%) [10]D5. Radioactive stents (iodine-125) reduce restenosis (11.9% vs 27.0%; HR 0.387) [40]B3b. Adverse events in 22-32%: obstruction (11.9%), migration (4.2-14.3%), perforation (2.1%) [8]B3b[12]D5. Additional palliative treatment after stenting prolongs patency (143.3 vs 67.6 days) and OS (169.0 vs 96.4 days) [8]B3b. Palliative radiotherapy: to primary tumor improves median OS (23.3 vs 14.0 months) and time to local progression (17.3 vs 8.3 months) in metastatic disease responding to chemotherapy [11]D5. Brachytherapy: HDR-BT with fractionation 3×5 Gy (boost) or 6×5 Gy (exclusive/reirradiation); median OS 15 months overall; grade 2+ toxicity 40% [7]C4. Photodynamic therapy (PDT): Improves dysphagia score from 2.75 to 1.05 at 4 weeks; 90% response rate; median survival 7.0 months [6]B2b. Compared to stenting, PDT provides similar relief at 1 and 3 months but longer time to re-obstruction [39]C4. Surgical diversion: In selected patients with cervical node metastases, neoadjuvant therapy followed by surgery may achieve median OS 24.2 months vs 18.0 months with definitive CRT (HR 0.56) [1]B2b. Pearl: When choosing a palliative procedure, consider prior radiotherapy: low radial force stents reduce adverse events after RT, and radioactive stents decrease restenosis. For patients with controlled metastatic disease, adding palliative RT to the primary tumor may prolong survival.
| Stent Type | Key Features | Advantages | Disadvantages |
|---|---|---|---|
| Covered SEMS | Silicone/polyurethane covering | Reduces tumor ingrowth; preferred for fistulas | Higher migration risk |
| Uncovered SEMS | No covering | Lower migration | Higher obstruction risk (OR 3.56 vs covered) [8]B3b |
| Low radial force (Niti-S) | Reduced expansion force | Safe after RT; major AE 6.3% [10]D5 | May have less effective dilation |
| Radioactive (I-125) | Seeds embedded in stent | Reduces restenosis (11.9% vs 27.0%) [40]B3b | No survival benefit; radiation exposure |
| Antimigration (multisegmented FCSEMS) | Novel design to prevent migration | Migration rate 9.4% [12]D5 | Limited data |
End-of-Life Care and Hospice
- ▸Early hospice referral improves quality of life.
- ▸Manage dumping syndrome and reflux proactively.
Hospice eligibility: Appropriate when life expectancy ≤6 months. Median OS with best supportive care is 3.2 months for cervical node metastasis [1]B2b; for brain metastases, pooled median OS is 5.62 months [31]B2a. ctDNA levels may refine prognosis: highest quartile associated with shorter OS (5.5 vs 9.9 months; HR 2.2) [41]B2b. Advance care planning: Prioritize patients with stable-low (5%) or deteriorating (14%) HRQoL trajectories [26]B2b. Elicit values, designate proxy, discuss code status. Terminal symptom management: Progressive dysphagia managed with stenting, gastrostomy, or oral comfort care. Dumping syndrome after esophagectomy: 78% prevalence; manage with small frequent meals, low simple sugars, acarbose, octreotide [24]B2b. Reflux: Common; use PPIs, prokinetics, head-of-bed elevation. Brain metastases: Incidence 2.84%; adenocarcinoma > squamous; resection improves survival (HR 0.45); whole-brain RT and corticosteroids for symptoms [31]B2a. Final days: Discontinue non-essential meds; manage secretions, dyspnea, agitation; ensure family support.
| Question | Position A | Position B | Strength | Implication |
|---|---|---|---|---|
| When to initiate hospice? | At diagnosis of incurable disease with expected survival <6 months | Only when all disease-modifying therapy is exhausted | Consensus | Earlier referral improves quality of life; no evidence that concurrent palliative chemotherapy precludes hospice |
| Role of artificial nutrition at end of life | Percutaneous gastrostomy may prolong survival in selected patients | Artificial nutrition does not improve comfort and may cause harm | Conditional | Shared decision-making based on patient goals; in terminal phase, focus on oral comfort care |
Pearl: The median survival of 3.2 months with best supportive care [1]B2b and the 5% stable-low HRQoL trajectory [26]B2b identify patients who benefit most from early hospice referral, do not wait for a clear terminal event.
| Parameter | Estimate | Source |
|---|---|---|
| Median OS, best supportive care (cervical node mets) | 3.2 months | [1]B2b |
| Median OS after brain metastasis diagnosis | 5.62 months (95% CI 3.98-7.94) | [31]B2a |
| Pooled incidence of brain metastases | 2.84% (adenocarcinoma 5.34%, SCC 1.45%) | [31]B2a |
| HRQoL stable-low trajectory | 5% of patients | [26]B2b |
| HRQoL deteriorating trajectory | 14% of patients | [26]B2b |
| Dumping syndrome prevalence (ever) | 78% | [24]B2b |
Related Pages
- ▸Use child pages for detailed management of specific modalities.
- ▸Parent page provides diagnosis and staging context.
Part of the Esophageal Cancer family. Cross-cutting management is split across dedicated child pages:
- , diagnostic page (definition, epidemiology, staging, biomarkers, prognosis)
- Esophageal Cancer Surgical Management , operations by stage, fertility-sparing options, sentinel node mapping, adjuvant triggers (Sedlis / Peters)
- , EBRT + image-guided brachytherapy + concurrent chemoradiation, dose / fractionation, OAR constraints
- Esophageal Cancer Systemic Therapy , concurrent / adjuvant / metastatic chemotherapy, targeted therapy, immune checkpoint inhibitors
- Esophageal Cancer Surveillance and Follow-up , post-treatment surveillance schedule, late toxicity, survivorship, patient counselling
- Esophageal Cancer Recurrent and Metastatic Disease , local-regional salvage, distant metastatic systemic therapy, oligometastatic disease
Pearl: Use these links to hop between management modalities; the parent Esophageal Cancer page carries diagnosis + staging that informs every decision here.
References
- [1]
Sanders ME, van der Horst S, Weijs TJ et al.. “Treatment strategies of esophageal cancer with concurrent cervical node metastasis: a Dutch nationwide population-based cohort study.” Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus (2026). PMID: 42043275 ↗
L2PROSPECTIVE_COHORTCited in: When to Integrate Palliative Care, Psychosocial, Spiritual, and Caregiver Support, Palliative Procedures, End-of-Life Care and Hospice - [2]
Butter R, Lagarde SM, van Oijen MGH et al.. “Treatment strategies in recurrent esophageal or junctional cancer.” Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus (2017). PMID: 28859371 ↗
L3COHORTCited in: When to Integrate Palliative Care - [3]
Battaglia G, Antonello A, Realdon S et al.. “Feasibility, efficacy and safety of stent insertion as a palliative treatment for malignant strictures in the cervical segment of the esophagus and the hypopharynx.” Surgical endoscopy (2015). PMID: 25829063 ↗
L4COHORTCited in: When to Integrate Palliative Care, Palliative Procedures - [4]
Machado AA, Martins BC, Josino IR et al.. “Impact of radiotherapy on adverse events of self-expanding metallic stents in patients with esophageal cancer.” Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus (2023). PMID: 37039273 ↗
L4COHORTCited in: When to Integrate Palliative Care, Palliative Procedures - [5]
Cincibuch J, Mysliveček M, Melichar B et al.. “Metastases of esophageal carcinoma to skeletal muscle: single center experience.” World journal of gastroenterology (2012). PMID: 23002370 ↗
L4RETROSPECTIVE_COHORTCited in: When to Integrate Palliative Care, Palliative Procedures - [6]
Yoon HY, Cheon YK, Choi HJ et al.. “Role of photodynamic therapy in the palliation of obstructing esophageal cancer.” The Korean journal of internal medicine (2012). PMID: 23019392 ↗
L2NON_RANDOMIZED_TRIALCited in: When to Integrate Palliative Care, Palliative Procedures - [7]
Kissel M, Chirat E, Annede P et al.. “Esophageal brachytherapy: Institut Gustave Roussy's experience.” Brachytherapy (2020). PMID: 32444283 ↗
L4RETROSPECTIVE_COHORTCited in: When to Integrate Palliative Care, Palliative Procedures - [8]
Kim JY, Kim SG, Lim JH et al.. “Clinical outcomes of esophageal stents in patients with malignant esophageal obstruction according to palliative additional treatment.” Journal of digestive diseases (2015). PMID: 26316005 ↗
L3COHORTCited in: When to Integrate Palliative Care, Palliative Procedures - [9]
Dijksterhuis WPM, Verhoeven RHA, Slingerland M et al.. “Heterogeneity of first-line palliative systemic treatment in synchronous metastatic esophagogastric cancer patients: A real-world evidence study.” International journal of cancer (2019). PMID: 31340065 ↗
L5OTHERCited in: When to Integrate Palliative Care - [10]
Ishioka M, Yoshio T, Sasaki T et al.. “Safety and Efficacy of Self-Expandable Metallic Stent Placement Using Low Radial Force Stent for Malignant Dysphagia after Radiotherapy.” Digestion (2022). PMID: 35184058 ↗
L5OTHERCited in: When to Integrate Palliative Care, Palliative Procedures - [11]
Hingorani M, Dixit S, Johnson M et al.. “Palliative Radiotherapy in the Presence of Well-Controlled Metastatic Disease after Initial Chemotherapy May Prolong Survival in Patients with Metastatic Esophageal and Gastric Cancer.” Cancer research and treatment (2015). PMID: 25687854 ↗
L5OTHERCited in: When to Integrate Palliative Care, Palliative Procedures - [12]
Noh JH, Gong EJ, Kim DH et al.. “Efficacy and safety of a novel multisegmented fully covered self-expanding metal stent for malignant esophageal obstruction: a prospective pilot study with historical control.” Surgical endoscopy (2024). PMID: 39653861 ↗
L5OTHERCited in: When to Integrate Palliative Care, Palliative Procedures - [13]
Wei ZD, Zhang HL, Yang YS et al.. “Effectiveness of Transthoracic Hybrid Minimally Invasive Esophagectomy: A Meta-Analysis.” Journal of investigative surgery : the official journal of the Academy of Surgical Research (2020). PMID: 32036710 ↗
L1SR_MA_RCTCited in: Symptom Management - [14]
Tsou YK, Liu CY, Fu KI et al.. “Endoscopic Submucosal Dissection of Superficial Esophageal Neoplasms Is Feasible and Not Riskier for Patients with Liver Cirrhosis.” Digestive diseases and sciences (2016). PMID: 27770376 ↗
L4COHORTCited in: Symptom Management - [15]
Kitagawa D, Kanesaka T, Ishihara R et al.. “Characteristics and Risk Factors for Postoperative Bleeding Following Endoscopic Resection of Esophageal Squamous Neoplasms.” Digestive diseases and sciences (2024). PMID: 39633230 ↗
L4COHORTCited in: Symptom Management - [16]
Kim DH, Jung HY, Gong EJ et al.. “Endoscopic and Oncologic Outcomes of Endoscopic Resection for Superficial Esophageal Neoplasm.” Gut and liver (2015). PMID: 25473069 ↗
L5OTHERCited in: Symptom Management - [17]
Yao J, Li J, Wang P et al.. “A novel technique using high energy synchronous double-wave laser in endoscopic submucosal dissection of patients with superficial esophageal neoplasm.” Endoscopy (2018). PMID: 29883978 ↗
L5OTHERCited in: Symptom Management - [18]
Joo DC, Kim GH, Park DY et al.. “Long-term outcome after endoscopic submucosal dissection in patients with superficial esophageal squamous cell carcinoma: a single-center study.” Gut and liver (2014). PMID: 25368748 ↗
L5OTHERCited in: Symptom Management - [19]
Yanasoot A, Yolsuriyanwong K, Ruangsin S et al.. “Costs and benefits of different methods of esophagectomy for esophageal cancer.” Asian cardiovascular & thoracic annals (2017). PMID: 28871799 ↗
L5OTHERCited in: Symptom Management - [20]
Kohn GP, Litle V, Eliya Y et al.. “ISDE guidelines on the management of cT2N0 esophageal cancer.” Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus (2026). PMID: 41785274 ↗
L1GUIDELINECited in: Psychosocial, Spiritual, and Caregiver Support, End-of-Life Care and Hospice - [21]
Jiang W, Huang Y, Pang J et al.. “Diagnostic accuracy of magnifying Image-enhanced endoscopy for predicting the invasion depth of superficial esophageal neoplasm: a meta-analysis.” European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology (2026). PMID: 42097052 ↗
L2SR_COHORTCited in: Psychosocial, Spiritual, and Caregiver Support, End-of-Life Care and Hospice - [22]
Yasuda T, Matsuda A, Hagiwara N et al.. “Rethinking Perioperative Corticosteroids in Esophageal Cancer Surgery: Evidence From an Integrative Meta-Analysis.” Annals of gastroenterological surgery (2026). PMID: 42395126 ↗
L1SR_MA_RCTCited in: Psychosocial, Spiritual, and Caregiver Support, End-of-Life Care and Hospice - [23]
Zhu Y, Qi X, Ni S et al.. “First-Line Serplulimab versus Other Anti-PD-1/PD-L1 Antibodies Plus Chemotherapy for Esophageal Squamous Cell Carcinoma: A Systematic Review with Benefit-Risk Assessment via Matching-Adjusted Indirect Comparison.” Biologics : targets & therapy (2026). PMID: 41788456 ↗
L1SR_MA_RCTCited in: Psychosocial, Spiritual, and Caregiver Support, End-of-Life Care and Hospice - [24]
Axelgaard I, Mucha AW, Nerup NA et al.. “Dumping Syndrome After Esophagectomy: Prevalence and Predictors in Gastroesophageal Cancer Patients.” The Journal of surgical research (2026). PMID: 42139856 ↗
L2PROSPECTIVE_COHORTCited in: Psychosocial, Spiritual, and Caregiver Support, End-of-Life Care and Hospice - [25]
Turkot MH, Yusuf A, Nowicki-Osuch K et al.. “Feasibility and Diagnostic Accuracy of a Capsule-sponge Device for Esophageal Squamous Neoplasia (EDEN Trial).” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2026). PMID: 41628756 ↗
L4PROSPECTIVE_COHORTCited in: Psychosocial, Spiritual, and Caregiver Support, End-of-Life Care and Hospice - [26]
Deuning-Smit E, Vos JAM, Motazedi E et al.. “Longitudinal health-related quality of life profiles in esophageal cancer: insights from a nationwide prospective observational cohort study.” Journal of cancer survivorship : research and practice (2026). PMID: 41555149 ↗
L2PROSPECTIVE_COHORTCited in: Psychosocial, Spiritual, and Caregiver Support, End-of-Life Care and Hospice - [27]
Kato K, Kojima T, Hara H et al.. “First-line pembrolizumab plus chemotherapy versus chemotherapy alone for advanced esophageal cancer: 5-year extended follow-up in the Japanese subgroup of KEYNOTE-590.” Esophagus : official journal of the Japan Esophageal Society (2026). PMID: 42047965 ↗
L1RCTCited in: Psychosocial, Spiritual, and Caregiver Support, End-of-Life Care and Hospice - [28]
de Oliveira JF, Martins BC, Moura RN et al.. “Randomized trial of intralesional steroid injection versus oral prednisolone for preventing esophageal stricture after extensive endoscopic submucosal dissection.” Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus (2026). PMID: 41926323 ↗
L1RCTCited in: Psychosocial, Spiritual, and Caregiver Support, End-of-Life Care and Hospice - [29]
Harada T, Sato H, Okura K et al.. “Preoperative risk factors for postoperative pneumonia in patients with esophageal cancer: A systematic review and meta-analysis.” Surgery today (2026). PMID: 42234145 ↗
L2SR_COHORTCited in: Psychosocial, Spiritual, and Caregiver Support, End-of-Life Care and Hospice - [30]
Xue W, Valderrama A, Ramakrishnan K et al.. “Event-free survival as a surrogate for overall survival in locally advanced esophageal cancer: a correlation analysis of trials assessing definitive chemoradiation therapies.” BMC cancer (2026). PMID: 41963862 ↗
L1SR_MA_RCTCited in: Psychosocial, Spiritual, and Caregiver Support, End-of-Life Care and Hospice - [31]
Hong H, Ding J, Yuan C et al.. “Incidence and prognosis of brain metastases in esophageal carcinoma: a systematic review and meta-analysis.” Journal of thoracic disease (2025). PMID: 41229813 ↗
L2SR_COHORTCited in: Psychosocial, Spiritual, and Caregiver Support, End-of-Life Care and Hospice - [32]
Ikeda T, Noma K, Okura K et al.. “Preoperative exercise capacity as a predictor of postoperative pulmonary complications in patients with esophageal cancer: a multicenter observational cohort study.” Esophagus : official journal of the Japan Esophageal Society (2026). PMID: 42380723 ↗
L3RETROSPECTIVE_COHORTCited in: Psychosocial, Spiritual, and Caregiver Support, End-of-Life Care and Hospice - [33]
Xue Z, Beijia L, Qin X et al.. “Clinical predictors of early reflux and symptom severity after esophagectomy: a risk prediction tool.” Esophagus : official journal of the Japan Esophageal Society (2026). PMID: 42380722 ↗
L3RETROSPECTIVE_COHORTCited in: Psychosocial, Spiritual, and Caregiver Support, End-of-Life Care and Hospice - [34]
Kosumi K, Harada K, Shimogawa T et al.. “Early Tumor Shrinkage and Clinical Outcomes for Esophageal Squamous Cell Carcinoma Patients Treated with Immune Checkpoint Inhibitors: Real-World Observational Study.” Annals of surgical oncology (2026). PMID: 42201494 ↗
L3COHORTCited in: Psychosocial, Spiritual, and Caregiver Support, End-of-Life Care and Hospice - [35]
Yoshida M, Urabe Y, Kadota T et al.. “Size and Macroscopic Type of Type B2 Vessel Areas in JES Classification for Predicting Invasion Depth: A Multicenter Prospective Study.” Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society (2026). PMID: 42144869 ↗
L3COHORTCited in: Psychosocial, Spiritual, and Caregiver Support, End-of-Life Care and Hospice - [36]
Matsui K, Miyawaki Y, Suzuki Y et al.. “Relationship between immune-related adverse events and long-term survival in patients treated with immune checkpoint inhibitors for unresectable advanced or recurrent esophageal cancer.” Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus (2026). PMID: 42001475 ↗
L4RETROSPECTIVE_COHORTCited in: Psychosocial, Spiritual, and Caregiver Support, End-of-Life Care and Hospice - [37]
Wu F, Luo C, Zhou S et al.. “Recurrent laryngeal nerve lymph nodes status prediction after neoadjuvant therapy for thoracic esophageal squamous cell carcinoma.” Insights into imaging (2026). PMID: 41945240 ↗
L3RETROSPECTIVE_COHORTCited in: Psychosocial, Spiritual, and Caregiver Support, End-of-Life Care and Hospice - [38]
Kaname T, Sugawara K, Yagi K et al.. “Prognostic Impact of Cachexia Index in Patients Undergoing Surgery for Esophageal Cancer.” Annals of surgical oncology (2026). PMID: 41661478 ↗
L3COHORTCited in: Psychosocial, Spiritual, and Caregiver Support - [39]
Ding Y, Li W, Li B et al.. “[Comparison between photodynamic therapy and interventional esophageal stent implantation in dysphagia caused by advanced esophageal cancer].” Zhonghua yi xue za zhi (2020). PMID: 32074783 ↗
L4COHORTCited in: Palliative Procedures - [40]
Wang C, Zhu GY, Lu J et al.. “[Efficacy of a novel fully covered radioactive stent for advanced esophageal and gastric cardia cancer: a retrospective controlled study].” Zhonghua yi xue za zhi (2019). PMID: 31874491 ↗
L3COHORTCited in: Palliative Procedures - [41]
Iden CR, Øgaard N, Mustafa SM et al.. “Circulating tumor DNA-guided response evaluation in patients with previously treated gastroesophageal adenocarcinoma.” Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association (2026). PMID: 42176235 ↗
L2NON_RANDOMIZED_TRIALCited in: End-of-Life Care and Hospice
Backlinks
- ← Esophageal Cancer Systemic Therapy (Detailed)
- ← Esophageal Cancer Systemic Therapy
- ← Esophageal Cancer Surveillance and Follow-up
- ← Esophageal Cancer Recurrent and Metastatic Disease
- ← Esophageal Cancer Recurrent and Metastatic Disease (Detailed)
- ← Esophageal Cancer Surgical Management (Detailed)
- ← Esophageal Cancer Radiation Management (Detailed)
- ← Esophageal Cancer Surgical Management
- ← Esophageal Cancer (Detailed)
- ← Esophageal Cancer Surveillance and Follow-up (Detailed)